First-Line Afatinib in EGFR NSCLC Patients With Brain Mets First-Line Afatinib in EGFR NSCLC Patients With Brain Mets
A new study looks at the effectiveness of first-line afatinib for patients with EGFR-mutated NSCLC and brain metastasis in a real-world setting.Translational Lung Cancer Research
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Hematology | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Pathology | Study